Latest Blogs

Jan 21, 2022
Dr. Lewis E. Foxhall and Zuzanna Tittenbrun describe the International Cancer Control Partnership and ASCO's role as a member of this international collaborative.
Jan 20, 2022
What do we mean when we say that equity, diversity, and inclusion is not one thing, it’s everything?
Jan 06, 2022
Dr. Leslie M. Randall, Dr. Mark Stoler, and I explore the decline in cervical cancer incidence which has not corresponded to a decline in deaths from high-risk invasive disease. 
Dec 17, 2021
Dr. Anghel Adrian Udrea began his career in Romania at a time when professional opportunities were limited, and he has spent 3 decades working to make a difference for the next generation of Romanian oncologists.
Subscribe to this column

Gilberto Lopes, MD, FASCO, MBA

Gilberto de Lima Lopes Jr., MD, MBA, FAMS, a medical oncologist, is medical director for international programs and associate director for global oncology at the Sylvester Comprehensive Cancer Center and associate professor of clinical medicine at the University of Miami in Florida. He returned to the United States after 10 years in Asia and Latin America and has dedicated much of his time to the issues of cancer control and access to medications in low- and middle-income countries. Dr. Lopes is the editor in chief of ASCO's Journal of Global Oncology, associate editor for the ASCO eLearning Editorial Board, 2016-2017 chair of the International Clinical Trials Workshop Working Group, and global health track leader for the Cancer Education Committee, among other volunteer roles. Follow him on Twitter @GlopesMd.

Disclosure.

Jul 26, 2017
My coauthors and I identify deficiencies in prevention and screening efforts that could be acted upon to further reduce cervical cancer incidence and mortality in Latin America.
Mar 20, 2017
When the basics of cancer control are not in place, should we discuss targeted agents and immunotherapy in resource-constrained settings?
Oct 31, 2016
Hope springs eternal in the Brazilian economy and health care system, with cautious optimism for gains in oncology care.
Oct 04, 2016
Inequalities, especially in health care, breed discontent. We need better ways to continue incentivizing the development of new drugs while optimizing access. Biosimilars help, but they won't solve the whole problem.
Aug 01, 2016
The region has seen structural reforms in health care systems, better training of cancer professionals, new initiatives for populations at high risk, expansion of cancer registries and cancer plans, and implementation of policies to improve prevention, early diagnosis, and treatment.
Jul 11, 2016
Follow-on biologics are here to stay, and represent enormous potential for patients with cancer being treated in low- and middle-income countries.

Pages